MedPath

VR Therapy for Psychosis Negative Symptoms (V-NeST)

Not Applicable
Conditions
Psychosis
Schizophrenia
Interventions
Behavioral: Virtual Reality Therapy (V-NeST)
Other: Treatment as Usual
Registration Number
NCT03995420
Lead Sponsor
Institute of Psychiatry, London
Brief Summary

Background: Negative symptoms are typically observed in people with schizophrenia and indicate a loss or reduction of a normal function (e.g. reduced motivation and affect display). Despite being important predictors of people's recovery the development of interventions for negative symptoms received only very limited attention. There are currently no evidenced based therapies for these symptoms.

Aims: To test the feasibility and acceptability of a novel virtual reality assisted therapy, called Virtual Reality Supported Therapy for the Negative Symptoms of Psychosis (V-NeST).

Methods: This is a single (rater) blind randomised study with two conditions; V-NeST plus treatment-as-usual (TAU) vs. TAU alone. The study will recruit people with psychosis from NHS community care teams (in England). Assessments will be at baseline and 3-month post-randomisation. A nested qualitative study to identify the key themes associated with the acceptability of the overall study and intervention will be conducted. The study will assess key feasibility parameters such as: consent and availability for screening; eligibility; availability for assessment, randomisation and treatment retention. Acceptability will be assessed by considering: therapy session attendance and drop-out; in-depth feedback from service users interviews; acceptability of the research procedures and measures.

Participants will be assessed with measures of functioning levels and, negative symptoms . Analyses will evaluate the feasibility and analyses of clinical outcomes will be focused on descriptive statistics and confidence intervals for treatment effects. Population variances of the main outcomes will be estimated for future power calculations. A semi-structured interview will explore participants' experience of being recruited to the study, receiving V-NeST and identify barriers (and potential solutions) to treatment engagement.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Service users currently under the care of NHS psychosis services;
  • Aged over 18;
  • in a stable clinical condition (as judged by primary clinician)
  • with a documented episode of psychosis and/or a diagnosis of schizophrenia.
Exclusion Criteria
  • Recent antipsychotic medication change (i.e. in the last 3 weeks);
  • Moderate to severe learning disability
  • Insufficient English for therapy
  • Organic impairment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Virtual Reality Therapy (V-NeST)Virtual Reality Therapy (V-NeST)Participants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
Virtual Reality Therapy (V-NeST)Treatment as UsualParticipants in this arm will receive Virtual Reality Therapy (V-NeST) plus treatment as usual (TAU).
Treatment as UsualTreatment as UsualParticipants in this arm will receive treatment as usual (TAU) only.
Primary Outcome Measures
NameTimeMethod
the Goal Attainment Scale12 weeks

Measure assessing to degree of participant's individual goals achievement

Full description of the measure and scoring can be obtained from the reference below:

Logan TK. Goal Attainment Scaling - Applications, Theory, and Measurement - Kiresuk,Tj, Smith,a, Cardillo,Je. Contemp Psychol. 1995;40(10):984-5.

Baggio L, Buckley DJ. Detecting change in patient outcomes in a rural ambulatory rehabilitation service: the responsiveness of Goal Attainment Scaling and the Lawton Scale. Aust Health Rev. 2016;40(1):63-8.

Ng BF, Tsang HW. Evaluation of a Goal Attainment Program using the Goal Attainment Scale for Psychiatric In-patients in vocational rehabilitation. Work. 2000;14(3):209-16.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institute of Psychiatry, King's College London

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath